The FDA called off a panel review regarding the use of Eli Lilly and Co.'s antidepressant Cymbalta for chronic pain to give the agency more time to evaluate safety information on the indication. The company said it already submitted additional studies and continues "routine safety monitoring that isn't specific to the chronic pain application."

Full Story:

Related Summaries